Constitutional Delay of Growth and Puberty: Towards Evidence-based Treatment
NCT01797718 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 35
Last updated 2018-02-06
Summary
Boys with constitutional delay of growth and puberty (CDGP) should be offered evidence-based effective and safe treatment option. This study compares the effects of low-dose testosterone and aromatase inhibitor letrozole on pubertal progression. The hypothesis is that, in boys CDGP showing earliest signs of puberty, peroral letrozole (2.5 mg/d for 6 mo) induces faster biochemical and clinical progression of puberty as compared to low-dose intramuscular testosterone Rx (\~1mg/kg/mo for 6 mo). In addition, 10 or more boys who select watchful waiting instead of medication will provide background data on the natural progression of CDGP, and their data will not be used in primary statistical comparisons.
Conditions
- Constitutional Delay of Growth and Puberty
Interventions
- DRUG
-
Testosterone
1mg/kg every 4 weeks for 6 months
- DRUG
-
2.5mg daily for 6 months. Safety criteria: if testosterone level is above 30nM at 3 months, the dosage is reduced to 2.5mg every other day
Sponsors & Collaborators
-
Foundation for Paediatric Research, Finland
collaborator OTHER -
Helsinki University Central Hospital
lead OTHER
Principal Investigators
-
Taneli Raivio, MD, PhD · Helsinki University Central Hospital
-
Matti Hero, MD, PhD · Helsinki University Central Hospital
-
Tero Varimo, MD, PhD · Helsinki University Central Hospital
-
Päivi Miettinen, MD, PhD · Helsinki University Central Hospital
-
Jorma Toppari, MD, PhD · University of Turku
-
Hanna Huopio, MD, PhD · Kuopio University Central Hospital
-
Sirpa Tenhola, MD, PhD · Kymeenlaakso Central Hospital
-
Raimo Voutilainen, MD, PhD · Kuopio University Central Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 14 Years
- Max Age
- 17 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-10-31
- Primary Completion
- 2017-03-20
- Completion
- 2018-02-05
Countries
- Finland
Study Locations
More Related Trials
-
Growth Hormone Treatment of Children Diagnosed of Intrauterine Growth Retardation
NCT01697644 ·Status: COMPLETED ·Phase: PHASE4
-
Markers of Pubertal Suppression During Therapy for Precocious Puberty
NCT02006680 ·Status: TERMINATED
-
Study of Comprehensive Diagnosis and Treatment for Children Precocious Puberty
NCT02920515 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH) (MK-8962-043)
NCT03019575 ·Status: COMPLETED ·Phase: PHASE3
-
Long Term Effect of Somatropin in Subjects With Intrauterine Growth Retardation
NCT01734447 ·Status: COMPLETED ·Phase: PHASE4
-
Evolution Of Growth Rate In Children With Growth Retardation Due to Glucocorticosteroid Therapy And Treated By Genotonorm
NCT00163189 ·Status: COMPLETED ·Phase: PHASE3
-
Kisspeptin in the Evaluation of Delayed Puberty
NCT01438034 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of a High Dosage Compared to the Label Dosage of Somatropin in Early Pubertal Stage Children With Growth Hormone Deficiency
NCT00191165 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty
NCT05341115 ·Status: COMPLETED ·Phase: PHASE4
-
Prevention of Growth Retardation by Early Treatment With Growth Hormone (GH) in Children With CJA Treated by Corticosteroid Therapy
NCT00174291 ·Status: TERMINATED ·Phase: PHASE3
-
Evaluate the Efficacy and Safety of DWJ108J
NCT06025409 ·Status: UNKNOWN ·Phase: PHASE3
-
Natural History Study of Patients With Excess Androgen
NCT00250159 ·Status: RECRUITING
-
A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height
NCT00840944 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy and Safety of Growth Hormone Treatment in Children Small for Gestational Age
NCT00557336 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Growth Hormone Treatment in Juvenile Idiopathic Arthritis
NCT00420251 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of GH on Body Proportions and Final Height in X-Linked Hypophosphatemic Rickets
NCT00473187 ·Status: UNKNOWN ·Phase: PHASE1
-
Treatment With Recombinant Human Growth Hormone (GH) in Children With Short Stature Secondary to a Long Term Corticoid Therapy
NCT00174187 ·Status: TERMINATED ·Phase: PHASE3
-
A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)
NCT03695237 ·Status: COMPLETED ·Phase: PHASE3
-
Growth Hormone Therapy in Osteogenesis Imperfecta
NCT00001305 ·Status: COMPLETED ·Phase: PHASE3
-
Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome
NCT00266656 ·Status: COMPLETED ·Phase: PHASE4
-
Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature
NCT01248416 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy on Height in SGA Children Treated With Growth Hormone
NCT00184756 ·Status: COMPLETED ·Phase: PHASE3
-
Growth Response in Short Children Suffering From a Disease With Growth Retardation and Treated With Somatropin
NCT00488124 ·Status: COMPLETED ·Phase: PHASE2
-
Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome
NCT01518062 ·Status: COMPLETED ·Phase: PHASE4
-
Long-term Outcome of GnRH Analogues Treatment of Children With Idiopathic Central Precocious Puberty
NCT02790112 ·Status: UNKNOWN ·Phase: NA